Introduction {#Sec1}
============

The guidelines for an appropriate use of antibiotic therapy recommend de-escalation as soon as the culture sensitivity results are available.There was a great need to study the frequency of de-escalation, no change and escalation of antibiotics and its impact in septic patients in an Indian ICU setting in view of rising burden of drug resistance and health care cost.

Objectives {#Sec2}
==========

To determine the rate of de-escalation of the empiric antimicrobial treatment in ICU patients admitted with sepsis. The characteristics of antimicrobial treatment associated with de-escalation & its impact on ICU length of stay, hospital length of stay (LOS) and 30 day mortality were determined.

Methods {#Sec3}
=======

We carried out a prospective observational study enrolling patients admitted to the ICU with sepsis from 01/02/2014 to 01/03/2015. Both the medical and surgical units of the ICU were included. **\"No change\"** was defined as when empiric therapy was maintained without modification, **\"Escalation of therapy\"** was defined when there's a switch to or addition of an antibiotic with a broader spectrum, and **\"De-escalation\"** when there's a switch to or interruption of a drug class resulting in a less broad spectrum of coverage. If antimicrobial change consisted of escalation and de-escalation (i.e. switch to or addition of an antibiotic with a broader spectrum but also withdrawal of another antibiotic), the patient was assigned to \"escalation group\" for statistical analysis.

Results {#Sec4}
=======

The total number of patients enrolled were 315 out of which 17 patients were excluded due to death before culture results were available. The characteristics observed among the therapeutic strategy groups were seen in tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}.Table 1Patient characteristics with therapeutic strategy.VariableNo change nDe-escalation nEscalation nP valueNumber of patients1487476Age in years57.6257.8158.180.96HOSPITAL length of stay in days11.4110.6819.210.0001APACHE II score at admission15.315.8420.110.0001SOFA score at admission6.076.658.080.004Number of patients expired at 30 days after admission2010260.0001number of medical patients14464660.003Number of patients requiring vasopressors2016340.0001ICU length of stay in days5.856.2412.420.0001Table 2Patient characteristics with therapeutic strategy.VariableNo change nDe-escalation nEscalation nP valueNumber of initial empirical antibiotics 15826320.007Number of initial empirical antibiotics 2722636Number of initial empirical antibiotics 318228Most Common initial empirical antibioticbeta lactam +beta lactamase inhibitorCarbapenembeta lactam +beta lactamase inhibitor0.0001Most Common Escalated /De-escalated Antibioticbeta lactam +beta lactamase inhibitorbeta lactam +beta lactamase inhibitorCarbapenem followed by colistin0.0001Multi drug resistant organisms68340.0001ESBL organisms44100.0001Most Common Source of infectionLungLungLungH1N1 POSITIVE patients291060.062

The most common antibiotic after de-escalation& antibiotic in No Change group was Betalactam + beta lactamase inhibitor.

The statistically significant factors which increased the 30 day mortality are Escalation of antibiotics, Increased ICU LOS, Increased APACHE II and SOFA scores at admission, medical patients, vasopressor requirement, lung as the source of infection, Infection with MDR organisms.

The statistically significant factors which increased the ICU LOS are use of vasopressors, Comorbidities, APACHE II at admission, SOFA at admission, MDR organisms, escalation of antibiotic.

Conclusions {#Sec5}
===========

Escalation of antibiotics resulted in statistically significant increase in the mortality and increased length of stay in the ICU and hospital. No significant differences were observed with respect to ICU length of stay, Hospital length of stay and 30 day mortality among No Change & De Escalation groups.Figure 1**The characteristics of the overall group of patients.**Figure 2**Comparison between survivors and non survivors at 30 days.**

###### 

Prevalence of organisms in patient groups. The frequency of organisms in culture positive cases.

  ORGANISM ISOLATED                   NO CHANGE n   DE ESCALATION n   ESCALATION n   Total n (%)
  ----------------------------------- ------------- ----------------- -------------- -------------
  Fungal infections                   4             2                 8              14(9.39%)
  Non ESBL Gram Negative organisms    12            10                8              30(20.13%)
  ESBL Gram negative organisms        4             4                 10             18(12.08%)
  MDR organisms                       6             8                 34             48(32.21%)
  MRSA organisms                      0             6                 0              6(4.02%)
  MSSA organisms                      0             2                 2              4(2.68%)
  Vancomycin Resistant Enterococcus   2             0                 0              2(1.34%)
  Stenotrophomonas maltophila         4             4                 4              12(8.05%)
